https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-06 17:04:402026-03-06 17:08:55Hansa Biopharma participating at Leerink Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-06 17:04:402026-03-06 17:08:55Hansa Biopharma participating at Leerink Global Healthcare Conference
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-05 08:43:252026-03-05 08:43:40PDUFA Action Date for Hansa Biopharma’s Imlifidase BLA Set for December 19, 2026
https://www.optimumcomms.com/wp-content/uploads/2026/02/Synklino-logo-website.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-26 12:04:472026-02-26 12:04:47Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-26 09:08:472026-02-26 09:08:47Oncoinvent ASA: Second half 2025 results
https://www.optimumcomms.com/wp-content/uploads/2026/02/Link-Biologics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-24 08:51:582026-02-24 08:52:25Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-23 17:06:092026-02-23 17:06:09Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-20 09:39:312026-02-20 09:39:52Biocomposites to launch SYNICEM bone cement in UK to ease supply crisis
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-20 08:30:482026-02-20 10:05:48Philanthropic Partnership Backs Country-Led Research to Guide the Use of AI in Health
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-19 08:49:162026-02-19 08:49:16Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA
https://www.optimumcomms.com/wp-content/uploads/2026/02/Lario_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-19 08:31:492026-02-19 08:31:49Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
https://www.optimumcomms.com/wp-content/uploads/2026/02/Pharmaacelera_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-18 08:37:162026-02-18 08:37:16Pharmacelera raises €6M to expand in U.S. and build out its high speed, high accuracy, deep tech drug discovery platform
https://www.optimumcomms.com/wp-content/uploads/2026/01/FundaMental-Pharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-17 08:59:542026-02-17 08:59:54FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-17 08:31:212026-02-17 08:31:21Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin® at ESGO 2026
https://www.optimumcomms.com/wp-content/uploads/2026/01/Nucleome_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-16 09:01:552026-02-16 09:01:55Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-16 08:40:572026-02-16 08:40:57Oncoinvent ASA: Announces webcast presentation of second half 2025 results on Thursday 26 February 2026
https://www.optimumcomms.com/wp-content/uploads/2025/10/AmacaThera_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-02-11 08:46:392026-02-12 10:34:06AmacaThera Named Life Sciences Ontario Emerging Company of the YearWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
